Internship

Science Co-Op

Posted on 9/30/2024

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Cambridge, MA, USA

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
PowerPoint/Keynote/Slides
Requirements
  • Pursuing a BS or MS in biology, biochemistry, biomedical engineering, or related field of study with at least 1 year of relevant laboratory experience.
  • Must be a team player, comfortable working collaboratively and thriving in a fast-paced environment
  • Proficient in Excel, PowerPoint, and data analysis. Knowledge of GraphPad Prism or JMP.
  • Experience maintaining a lab notebook and following written protocols.
  • Motivated to learn and detail oriented with excellent organizational and communication skills.
Responsibilities
  • Formulate and characterize LNPs to determine size, polydispersity, concentration, encapsulation, and pKa using established assays and techniques
  • Participate in platform assay development, including testing of new materials and protocols
  • Evaluate the delivery of base editor technologies through in vitro and in vivo base editing studies
  • Document, summarize and present studies and findings to internal audience at group meetings
  • Document and manage all experimental planning and results in electronic lab notebook, including statistical analysis and troubleshooting where appropriate.
  • Adhere to all laboratory safety requirements and procedures, assist in maintaining general laboratory functionality, including maintenance of lab equipment and receiving of lab supplies

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Beam Therapeutics distinguishes itself from competitors by its commitment to rigorous scientific development and a values-driven approach, emphasizing the importance of its expert team in achieving its goal of delivering lasting cures for patients.

Company Stage

IPO

Total Funding

$215.9M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

1%

1 year growth

1%

2 year growth

-6%
Simplify Jobs

Simplify's Take

What believers are saying

  • Base editing technology is gaining traction as a precise genetic correction method.
  • The $250 million deal with Eli Lilly boosts Beam's financial and strategic position.
  • Christi Shaw's appointment to the board brings valuable biotech leadership.

What critics are saying

  • Competition from CRISPR Therapeutics could impact Beam's market share.
  • Recent restructuring and layoffs may lead to operational challenges.
  • New CFO transition might pose financial management challenges.

What makes Beam Therapeutics unique

  • Beam Therapeutics uses base editing, a precise genetic correction method.
  • The company focuses on lifelong cures for genetic disorders like sickle cell disease.
  • Beam's strategic partnerships, like with Eli Lilly, enhance its market position.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE